| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,370,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
| 52
Week Range: |
$76.22 - $99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 811 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,625 |
| Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
134,986 |
251,929 |
319,053 |
656,089 |
| Total Sell Value |
$11,097,511 |
$21,508,551 |
$27,661,182 |
$61,420,002 |
| Total People Sold |
5 |
6 |
7 |
7 |
| Total Sell Transactions |
9 |
19 |
27 |
56 |
| End Date |
2024-04-04 |
2024-01-02 |
2023-07-04 |
2022-07-04 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Davis George Eric |
EVP, General Counsel |
• – – |
2018-03-05 |
4 |
AS |
$79.04 |
$166,379 |
D/D |
(2,105) |
90,089 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2018-03-02 |
4 |
D |
$79.86 |
$128,894 |
D/D |
(1,614) |
58,304 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2018-03-02 |
4 |
D |
$79.86 |
$128,974 |
D/D |
(1,615) |
79,469 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2018-03-02 |
4 |
D |
$79.86 |
$682,164 |
D/D |
(8,542) |
264,674 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2018-03-02 |
4 |
OE |
$14.39 |
$14,390 |
D/D |
1,000 |
273,216 |
|
- |
|
| Fuchs Henry J |
President, Worldwide R&D |
• – – |
2018-03-02 |
4 |
D |
$79.86 |
$205,719 |
D/D |
(2,576) |
151,309 |
|
- |
|
| Spiegelman Daniel K |
EVP, Chief Financial Officer |
• – – |
2018-03-02 |
4 |
D |
$79.86 |
$128,495 |
D/D |
(1,609) |
68,520 |
|
- |
|
| Davis George Eric |
EVP, General Counsel |
• – – |
2018-03-02 |
4 |
D |
$79.86 |
$165,390 |
D/D |
(2,071) |
92,194 |
|
- |
|
| Davis George Eric |
EVP, General Counsel |
• – – |
2018-02-26 |
4/A |
A |
$0.00 |
$0 |
D/D |
11,601 |
94,343 |
|
- |
|
| Fuchs Henry J |
President, Worldwide R&D |
• – – |
2018-02-26 |
4/A |
A |
$0.00 |
$0 |
D/D |
20,463 |
154,024 |
|
- |
|
| Spiegelman Daniel K |
EVP, Chief Financial Officer |
• – – |
2018-02-26 |
4/A |
A |
$0.00 |
$0 |
D/D |
12,615 |
70,215 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2018-02-26 |
4/A |
A |
$0.00 |
$0 |
D/D |
12,274 |
81,168 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2018-02-26 |
4/A |
A |
$0.00 |
$0 |
D/D |
12,615 |
60,004 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2018-02-26 |
4/A |
A |
$0.00 |
$0 |
D/D |
46,034 |
272,528 |
|
- |
|
| Fuchs Henry J |
President, Worldwide R&D |
• – – |
2018-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
20,324 |
153,885 |
|
- |
|
| Davis George Eric |
EVP, General Counsel |
• – – |
2018-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
11,523 |
94,265 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2018-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
45,722 |
272,216 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2018-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
12,529 |
59,918 |
|
- |
|
| Spiegelman Daniel K |
EVP, Chief Financial Officer |
• – – |
2018-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
12,529 |
70,129 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2018-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
12,190 |
81,084 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2018-02-15 |
4 |
AS |
$84.63 |
$846,285 |
D/D |
(10,000) |
226,494 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2018-02-15 |
4 |
OE |
$38.59 |
$385,900 |
D/D |
10,000 |
236,494 |
|
- |
|
| Davis George Eric |
EVP, General Counsel |
• – – |
2018-02-01 |
4 |
AS |
$90.66 |
$2,719,665 |
D/D |
(30,000) |
82,942 |
|
- |
|
| Davis George Eric |
EVP, General Counsel |
• – – |
2018-02-01 |
4 |
OE |
$38.59 |
$1,157,700 |
D/D |
30,000 |
112,942 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2018-01-05 |
4 |
AS |
$90.32 |
$903,203 |
D/D |
(10,000) |
225,894 |
|
- |
|
1285 Records found
|
|
Page 31 of 52 |
|
|
1.44 (1.6%) 
